A recent Fierce Biotech article explores how the FDA’s Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations can help accelerate the development of promising cancer therapies. The key takeaway? Success isn’t just about qualifying for an expedited pathway—it’s about making the right regulatory decisions early, building a strong clinical evidence package, and ensuring manufacturing is ready to keep pace.
For life sciences organizations, bringing together experienced regulatory, clinical, quality, and manufacturing leaders is critical to navigating these complex development pathways successfully.
At The Bandish Group, we’ve spent 30 years helping biotech and pharmaceutical companies connect with the specialized talent needed to move innovative therapies from development to patients.
Click here to read the entire article.
